Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model-Reference-Cited by-同舟云学术

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Matsumoto Shuhei¹^ORCID,Kanazawa Sachi²,Sato Takafumi²,Yamano Yoshinori²

Affiliation:

1. Business Development, Shionogi & Co., Ltd., Osaka, Japan

2. Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan

Abstract

Activities of cefiderocol under simulated human plasma concentrations at the recommended dosing regimen of 2 g every 8 h with a 3-h infusion were evaluated using an in vitro chemostat model. Against a total of 6 meropenem-resistant Gram-negative strains with cefiderocol MICs of 0.5 to 4 μg/ml, including metallo-β-lactamase producers and carbapenem-resistant Acinetobacter baumannii , cefiderocol treatment showed a bactericidal effect within 8 h and sustained efficacy with no marked bacterial regrowth over 24 h.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01128-20

Reference19 articles.

1. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

2. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

3. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

4. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms

5. FDA. 2019. Cefiderocol injection. FDA, Silver Spring, MD. https://www.fda.gov/drugs/development-resources/cefiderocol-injection.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae;Antimicrobial Agents and Chemotherapy;2023-09-19

2. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales;Infectious Diseases and Therapy;2023-02-25

3. Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol;Expert Review of Anti-infective Therapy;2022-05-10

4. Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models;JAC-Antimicrobial Resistance;2022-05-03

5. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence;Frontiers in Pharmacology;2022-04-12